Golimumab, SCH 900259, MK-8259, CNTO-148: A Comparative Review This analysis reviews four unique therapies : golimumab, SCH 900259, MK-8259, and CNTO-148. Golimumab, a well-established monoclonal targeting TNF-alpha, functions as a reference against which the novel compounds—SCH 900259 (a investigational inhibitor), MK-8259 (focusing o… Read More
Vantictumab, formerly known as OMP18R5, represents the novel targeted body designed for specifically block bone associated protein 18R5. The approach is actively developed by the company for potential treatments in several bone disorders, particularly those involving excessive bone loss. Preclinical data suggest Vantictumab is able to effectivel… Read More